Impact of APOE genotype on cognition in idiopathic and genetic forms of Parkinson's disease.

BackgroundApolipoprotein E-{varepsilon}4 (APOE {varepsilon}4) genotype may be associated with the development of cognitive decline in idiopathic Parkinsons disease i(PD), however its effect in genetic PD is understudied. ObjectivesIn the current work we aimed to assess the impact of APOE genotype on cognition in iPD as well as in genetic PD with mutations in the Alpha-synuclein (SNCA) and Glycocerebrosidase (GBA1) genes. MethodsTwo independent PD cohorts were analyzed: The first cohort (Athens) included 50 iPD patients, 35 patients with the p.A53T SNCA mutation and 59 patients with GBA1 mutations (13 mild /46 severe). The second cohort (Tubingen) included 292 patients with GBA1 mutations (170 risk/ 52 mild/ 70 severe). All patients underwent cognitive testing and were genotyped for APOE. ResultsIn the iPD subgroup, carriers of at least one APOE {varepsilon}4 exhibited lower Montreal Cognitive Assessment test (MoCA) score as compared to non-carriers (p=0.044). Notably, in the p.A53T SNCA subgroup, APOE {varepsilon}4 carriers also had lower MoCA scores compared to non-carriers (p=0.039). There were no APOE {varepsilon}4-related differences in the two GBA1 subgroups (Athens, p=0.729; Tubingen p=0.585). ConclusionsWe confirm the impact of APOE {varepsilon}4 on cognitive decline in iPD and for the first time report a similar effect in p.A53T SNCA mutation carriers, who represent the prototypical genetic synucleinopathy. Contrary, the lack of such an effect in two independent cohorts of GBA1 mutation carriers, who are thought to also manifest a predominant alpha-synuclein-driven cognitive decline, suggests differences in factors associated with cognitive dysfunction between different genetic forms of synucleinopathies.